A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Forced-dose Titration, Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
收藏DataCite Commons2025-03-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006702/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The study is designed to evaluate the efficacy and safety of each dose of SHP465 (12.5 and
37.5 mg) given to participants daily in the morning compared to placebo in the treatment of
adults aged 18 to 55 years diagnosed with ADHD.
提供机构：
Vivli
创建时间：
2021-02-18
